Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Sangamo Therapeutics, Inc.
Sangamo Therapeutics is a biotech company that develops gene therapies for serious neurological and inherited diseases.
Sangamo Therapeutics is a genomic medicine company working on a big and ambitious idea: fixing diseases at their source by editing or replacing the genes that cause them. The company focuses on serious neurological and inherited conditions, where standard drugs often can't do the job because the problem lives inside a patient's DNA. Sangamo's main tools are gene therapy and gene editing — treatments designed to correct faulty genes or deliver working copies into a patient's cells.
The business runs on a simple but expensive cycle. Sangamo's scientists build experimental therapies in the lab, test them in early human trials, and try to prove they are safe and effective. The company doesn't really sell a product yet; it earns money mainly through partnerships with larger drugmakers who pay for access to its gene-editing technology and help fund development. Its most important partnership is with Pfizer, which has worked with Sangamo on gene therapy programs for hemophilia. Sangamo also has collaborations with other biopharma partners, and these deals provide the cash that keeps the science moving. What makes Sangamo stand out is its pioneering work in zinc finger technology, a way of precisely targeting and editing DNA that the company has been developing for years, long before gene editing became a hot field. That head start gives it deep expertise, but it also means the company has spent a lot of money and time without yet bringing a therapy to market. Like most clinical-stage biotechs, Sangamo is a high-risk, high-reward story: it burns cash each quarter, depends on partners and investors to fund its research, and lives or dies on whether its treatments succeed in trials.
The company is headquartered in Brisbane, California, a hub of biotech activity near San Francisco. Sangamo is a bet on the future of genetic medicine, and its value hinges on turning that science into approved therapies. Investors are essentially paying for a promising pipeline and a stack of scientific expertise, hoping that one day a treatment reaches patients — and the market — at scale.
Saved answer · last researched 15 Nov 2026